Databricks CEO and co-founder Ali Ghodsi believes that the gap represents the next frontier for AI automation. In his view, the next generation of AI agents won’t just write software, but operate the ...

Using a tool to solve a protein's structure, for most researchers in the world of structural biology and computational chemistry, is not unlike using the Rosetta Stone to unlock the secrets of ancient ...

Research uncovering the origin of pineoblastoma, a rare pediatric brain tumor, has also revealed a dependency across multiple brain tumor types that share a similar molecular program.

SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S.

Genie has launched Genie Recon, a new reconditioning business focused on providing factory-refurbished aerial lifts for equipment owners seeking alternatives to purchasing new machines. The program ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 ...

Add Yahoo as a preferred source to see more of our stories on Google. A jury awarded $30 million to a former Newark student who charged that, starting in third grade in 1991, he was repeatedly raped ...

Jan 28 (Reuters) - Regenxbio (RGNX.O), opens new tab said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene therapy programs for rare ...

AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. (GNPX) ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...